{"entity":{"id":"luis-paz-ares","kind":"person","name":"Luis Paz-Ares","aka":[],"tldr":"Madrid medical oncologist who heads the joint 12 de Octubre-CNIO lung cancer clinical research unit and led the KEYNOTE-407 trial in squamous lung cancer.","summary":"Luis Paz-Ares heads the H12O-CNIO Lung Cancer Clinical Research Unit, a joint unit of Hospital Universitario 12 de Octubre and the Spanish National Cancer Research Centre (CNIO), and leads medical oncology at 12 de Octubre. He was first author of the KEYNOTE-407 trial that established pembrolizumab plus chemotherapy as first-line treatment for squamous non-small-cell lung cancer. His work spans thoracic oncology and early-phase drug development.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.cnio.es/en/research/research-programmes/clinical-research-programme/h12o-cnio-lung-cancer-clinical-research-unit/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Paz-Ares+L%5BAuthor%5D"}],"tags":["clinician-scientist","lung cancer","immunotherapy"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["12-de-octubre"],"pathways":[],"terms":[],"trials":["caspian","dellphi-304"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head of the H12O-CNIO Lung Cancer Clinical Research Unit","institutionId":"12-de-octubre","specialisms":["Lung cancer","Thoracic oncology","Early-phase clinical trials"],"profiles":[{"label":"Institution profile","url":"https://www.cnio.es/en/research/research-programmes/clinical-research-programme/h12o-cnio-lung-cancer-clinical-research-unit/"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Paz-Ares+L%5BAuthor%5D"}],"papers":[{"title":"Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer","journal":"New England Journal of Medicine","year":2018,"url":"https://doi.org/10.1056/NEJMoa1810865","doi":"10.1056/NEJMoa1810865"}],"orcid":"0000-0002-1947-3364"},"route":"/people/luis-paz-ares/","neighbours":{"cancer":[{"id":"extensive-stage-sclc","kind":"cancer","name":"Extensive-stage small-cell lung cancer","route":"/cancers/extensive-stage-sclc/"},{"id":"limited-stage-sclc","kind":"cancer","name":"Limited-stage small-cell lung cancer","route":"/cancers/limited-stage-sclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"institution":[{"id":"12-de-octubre","kind":"institution","name":"Hospital Universitario 12 de Octubre","route":"/institutions/12-de-octubre/"}],"trial":[{"id":"nct01828099","kind":"trial","name":"ASCEND-4","route":"/trials/nct01828099/"},{"id":"caspian","kind":"trial","name":"CASPIAN","route":"/trials/caspian/"},{"id":"dellphi-304","kind":"trial","name":"DeLLphi-304","route":"/trials/dellphi-304/"},{"id":"keynote-407","kind":"trial","name":"KEYNOTE-407","route":"/trials/keynote-407/"}],"paper":[{"id":"paper-keynote-189-407-tmb-jtocrr-2023","kind":"paper","name":"Associations of tissue tumour mutational burden and mutational status with clinical outcomes with pembrolizumab plus chemotherapy versus chemotherapy for metastatic non-small-cell lung cancer","route":"/key-papers/paper-keynote-189-407-tmb-jtocrr-2023/"},{"id":"paper-codebreak-200-lancet-2023","kind":"paper","name":"CodeBreaK 200: sotorasib versus docetaxel in KRAS G12C-mutated lung cancer, a modest win for the first KRAS drug","route":"/key-papers/paper-codebreak-200-lancet-2023/"},{"id":"paper-dellphi-301-nejm-2023","kind":"paper","name":"DeLLphi-301: tarlatamab, a DLL3-targeting T-cell engager, in previously treated small-cell lung cancer","route":"/key-papers/paper-dellphi-301-nejm-2023/"},{"id":"paper-paz-ares-caspian-durvalumab-es-sclc-lancet-2019","kind":"paper","name":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN)","route":"/key-papers/paper-paz-ares-caspian-durvalumab-es-sclc-lancet-2019/"},{"id":"paper-ascend-4-lancet-2017","kind":"paper","name":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","route":"/key-papers/paper-ascend-4-lancet-2017/"}]}}